RxDoctor Payments Data

Ronequa Evans, NP

Family · Jackson, MSNPI 1982205423

Payments from drug & device makers

$2,057in general payments, 2019–2025

Across 65 payments — averaging $31.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$494
  • Novartis$371
  • Bayer$295
  • Ardelyx, Inc.$177
  • Otsuka America Pharmaceutical, Inc.$149
  • Mallinckrodt Hospital Products Inc.$144
  • plus $426 from 7 others

What the payments were for

  • Food & beverage$2,057100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,057 in reported general payments places this provider in the 80th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$19,511
Medicare patients
146
Services billed
413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol64$68,492
JardianceEmpagliflozin34$37,312
Sevelamer Carbonate17$3,794
Nifedipine ErNifedipine82$3,641
Losartan Potassium96$977
Carvedilol90$780
Hydralazine Hcl52$730
Metoprolol Succinate20$611
Torsemide28$567
Potassium Chloride18$468
Tamsulosin Hcl14$463
Amlodipine Besylate90$457
Spironolactone50$444
Allopurinol54$444
Chlorthalidone21$345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$494$68,49264 claims
Boehringer IngelheimJardiance$55$37,31234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,007 family providers in Mississippi.

Other family in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →